by Agastiya Biotech | Apr 3, 2024 | Media
Vopec Pharmaceuticals and Agastiya Biotech Announce Breakthrough Phase 1 Study Results of Small Molecule AB001 for Multiple Metastatic Solid Tumors Vopec Pharmaceuticals and Agastiya Biotech today announced topline results from the Phase 1 study of AB001, an...
by Agastiya Biotech | May 3, 2022 | Media
Agastiya Biotech and Vopec Pharmaceuticals announce that the US FDA has granted Orphan Drug Designations for Pancreatic Cancer and AML for its novel small molecule, AB001. AB001 is a small molecule PD-L1 checkpoint inhibitor that also targets aberrant intracellular...
Recent Comments